Vytorin: Wave Two -- Impact of ENHANCE Trial
A Survey of One-Hundred Three US-based PCP’s and Cardiologists
Price $2500
Deliverable: Survey with key findings.
Study Description:
|
Topic |
|
|
Respondent Type |
Physicians |
|
Specialties Covered |
Primary Care and Cardiology |
|
Region |
United States Only |
|
Methodology |
Online survey, self-administered via a Panel Intelligence website Duration: 10 minutes Size: 72 PCP’s and 31 Cardiologists for 103 respondents Fielding Dates: April 1st to April 4th, 2008 |
Objectives:
To determine the impact of the ENHANCE study on Vytorin and Zetia use.
Companies and Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Product(s) |
|
AstraZeneca |
AZN |
Crestor |
|
Pfizer |
PFE |
Lipitor |
|
Merck/Schering-Plough Pharmaceuticals |
MRK/SGP |
Vytorin |
|
Merck/Schering-Plough Pharmaceuticals |
MRK/SGP |
Zetia |
|
Merck & Co |
MRK |
Zocor |
Inclusion Criteria and Respondent Demographics:
|
Inclusion Criteria |
§ US-based § 2 to 30 years of experience post-training § Minimum of 75% professional time spent in clinical practice § Writes at least 20 prescriptions for Zetia and Vytorin (combined) in an average month |
To purchase this report or request additional information, contact:
Print Abstract
For additional information on this study or to purchase, please call:
|
Survey
Cardiology |